https://www.live-feeds.com/feed/boehringer-returns-to-sino-biopharma-in-7-4b-deal-for-preclinical-tces-adcsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/boehringer-returns-to-sino-biopharma-in-7-4b-deal-for-preclinical-tces-adcshttps://www.live-feeds.com/feed/boehringer-returns-to-sino-biopharma-in-7-4b-deal-for-preclinical-tces-adcs#u191134Tue, 10 Nov 2026 12:30:06 +0000Boehringer Ingelheim has entered into a major oncology partnership with China's Sino Biopharma, securing rights to preclinical antibody-drug conjugates and T-cell engagers in a deal valued at over seven billion dollars. This agreement marks a return collaboration between the two companies focused on developing advanced cancer therapies. The transaction involves backloaded payments contingent upon successful clinical development and commercialization milestones. Industry analysts are closely monitoring how this partnership will expand Boehringer's targeted cancer portfolio through the